Ronald E. Savage - Concepedia

Author

Ronald E. Savage

Arqule (United States)ORCID

Also Known As

R E Savage, R. E. Savage, R. Savage, R.E. Savage, Ronald E Savage, Ronald E. Savage, Ronald Savage

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Arqule (United States)Cleveland Clinic Daiichi-Sankyo (Japan)Mary Crowley Cancer Research Center National Human Genome Research Institute

About

Ronald E. Savage is an author at Arqule (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	635
2	Biochemistry	4	4	193
3	Natural Sciences	2	2	123
4	Health Sciences	1	1	23
5	Biomolecular Engineering	1	1	105

Ronald E. Savage

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies Timothy A. Yap, David Olmos, André T. Brunetto, Journal of Clinical Oncology	2011	193
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials Enchi Liu, Mark E. Schmidt, Richard Margolin, Neurology	2015	149
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092 Yi Yu, Ronald E. Savage, Sudharshan Eathiraj, PLoS ONE Chemoprevention StrategyImmunologyCancer BiologyTumor BiologySignaling Pathway	2015	120
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel, Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyPharmaceutical ChemistryMolecular PharmacologyMedicinal Chemistry	2016	105
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher, British Journal of Cancer	2017	93
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors Lee S. Rosen, Neil Senzer, Tarek Mekhail, Clinical Cancer Research	2011	87
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome Kim M. Keppler‐Noreuil, Julie C. Sapp, Marjorie J. Lindhurst, The American Journal of Human Genetics Translational MedicineNeurological DisorderMedicineCerebrospinal FluidProteus Syndrome	2019	87
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation Terence Hall, Yi Yu, Sudharshan Eathiraj, PLoS ONE Fgfr PathwayImmunologyCancer BiologyTumor BiologyReceptor Tyrosine Kinase	2016	84
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies Jennifer A. Woyach, Deborah M. Stephens, Ian W. Flinn, Blood	2019	77
Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib Jonathan W. Goldman, Isett Laux, Ronald E. Savage, Cancer	2012	76

Page 1